Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
novartis india ltd
10 capsule(s) in a strip
Ceritinib
Keep in cold place
Delivering To:
Overview
Spexib 150mg Capsule is an anticancer medicine. It is used as a first line of treatment in patients with ALK-positive (anaplastic lymphoma kinase-positive) metastatic Non-small cell lung cancer. This Capsule belongs to a class of medicines known as protein kinase inhibitors. It works by blocking the activity of an abnormal protein that is responsible for the uncontrolled growth of cancer cells.
Non-small cell lung cancer
Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.
Some common side effects of Spexib 150mg Capsule include:
Blurred vision
Diarrhea
Loss of appetite
Abdominal pain
Skin Rash
Low blood pressure
Weight loss
Fever
Chills
Nausea
Vomiting
Tiredness or weakness
Difficulty in breathing
Irregular heartbeat
High blood pressure
Contact your healthcare provider if you face any unusual or persistent side effects.
Spexib 150mg Capsule is usually taken once a day as prescribed by the doctor. It should be taken with meals to reduce stomach upset and improve absorption. Follow your doctor's advice strictly regarding the dosage and duration.
Swallow the capsule as a whole with a glass of water. Do not crush, chew, or break the Capsule.
Alcohol
unsafe
Avoid the consumption of alcohol while taking Spexib 150mg Capsule, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
consult your doctor
Spexib 150mg Capsule is not recommended during pregnancy as it is unsafe for the developing fetus. Doctors rarely prescribe this medicine in pregnancy.
Breast Feeding
consult your doctor
Spexib 150mg Capsule is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Driving
danger
Spexib 150mg Capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Use of Spexib 150mg Capsule is safe in patients with kidney disease. No dose adjustment is recommended for this medicine.
Liver
caution
Use of Spexib 150mg Capsule is safe in patients with liver disease. No dose adjustment is recommended for this medicine, but it is required to consult a doctor before starting the medicine.
If you miss a dose of this medicine, call your physician right away to learn the ways of coping with the skipped dose.
Spexib 150mg Capsule is an anticancer drug prescribed to treat Non-small cell lung cancer (NSCLC).
Take Ceritinib capsules orally as prescribed by your doctor. Do not increase or decrease the dose strength or stop taking this medication without consulting a qualified medical practitioner.
The side effects of Spexib 150mg Capsule include fatigue, nausea, vomiting, diarrhea, high blood pressure, irregular heartbeat, pale skin, dizziness, blurred vision, bleeding, seizures, etc.
In case of an overdose, the patient is advised to consult a health professional immediately if any unusual symptoms occur.
Ceritinib capsules are not indicated for use in pregnant women.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1. Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., ... & Pazdur, R. (2015). FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer. Clinical cancer research, 21(11), 2436-2439.
2.https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPrescribingInfo/9Ceritinib.pdf
3. Dhillon, S., & Clark, M. (2014). Ceritinib: first global approval. Drugs, 74(11), 1285-1291.
4. Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., ... & Shaw, A. T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. The lancet oncology, 17(4), 452-463.
5. Cooper, M. R., Chim, H., Chan, H., & Durand, C. (2015). Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Annals of Pharmacotherapy, 49(1), 107-112.
6. Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., ... & de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet, 389(10072), 917-929.
novartis india ltd
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.